Champions Oncology, Inc. Ownership
$5.05
2.02%
Nasdaq, Sep 17, 03:58 pm EDT.
Closed.
Index
Industry
Champions Oncology, Inc. Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Battery Management Corp
|
2.422m | 17.43% | — | Mar 31 2026 |
| 2 |
New Enterprise Associates (NEA)
|
1.714m | 12.34% | — | Mar 31 2026 |
| 3 |
Ackerman (Joel)
|
1.057m | 7.61% | +94.405k | Oct 30 2025 |
| 4 |
West Elk Capital, LLC
|
882.581k | 6.35% | -210.806k | Sep 30 2024 |
| 5 |
Morris (Ronnie)
|
858.878k | 6.18% | — | Aug 22 2025 |
|
1
Battery Management Corp
|
17.43%
2.422m
|
|
2
New Enterprise Associates (NEA)
|
12.34%
1.714m
|
|
3
Ackerman (Joel)
|
7.61%
1.057m
|
|
4
West Elk Capital, LLC
|
6.35%
882.581k
|
|
5
Morris (Ronnie)
|
6.18%
858.878k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 49.92% of Champions Oncology, Inc., with Battery Management Corp the biggest at 17.43%, followed by New Enterprise Associates (NEA) (12.34%) and Ackerman (Joel) (7.61%). |
Recent Champions Oncology, Inc. Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Sep 18 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 15 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 11 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 06 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Aug 31 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Aug 24 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Sep 18 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 15 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 11 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 06 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Aug 31 2026
$170.50
|
|
Lisa Park
SALES
|
Aug 24 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Champions Oncology, Inc. Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Champions Oncology, Inc. has held steady at around 1.1% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
